iBio

iBio Net Debt

The Net Debt of iBio (IBIO) as of Nov 17, 2026 is -85.84 M USD. In the previous year, Net Debt was -5.07 M USD — a change of 1,591.78% (lower).

Net Debt

-85.84 MUSD

YoY

1,591.78%

Last updated:

Net Debt of iBio is 2026 -85.84 M USD. Net Debt of iBio was 2025 -5.07 M USD. It decreases by 1,591.78% lower compared to the previous year.

The iBio Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2019
20.46 M USD
Jan 1, 2020
-22.20 M USD
Jan 1, 2021
-64.25 M USD
Jan 1, 2022
-7.76 M USD
Jan 1, 2023
9.75 M USD
Jan 1, 2024
-9.75 M USD
Jan 1, 2025
-5.07 M USD
Jan 1, 2026
-85.84 M USD
The iBio Net Debt history
YEARNet DebtYoY
-85.84 MUSD+1,591.78%
-5.07 MUSD-47.96%
-9.75 MUSD-200.02%
9.75 MUSD-225.70%
-7.76 MUSD-87.93%
-64.25 MUSD+189.37%
-22.20 MUSD-208.51%
20.46 MUSD+123.71%
9.15 MUSD-46.75%
17.18 MUSD+609.50%
2.42 MUSD-125.50%
-9.49 MUSD+164.46%
-3.59 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

iBio Stock analysis

What does iBio do? iBio, Inc. generates revenue through the commercialization of its plant-based protein expression technologies, which are used for developing vaccines and therapeutic proteins. The company's iBioLaunch technology and iBioModulator platform enable the production of biologics in hydroponically grown green plants, targeting fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of plasma-derived products. Clients and collaborators purchase product development and manufacturing services, leveraging iBio's transformative platform for biologics production. The firm focuses on both its own product candidates and providing services to external partners in the biopharmaceutical sector. iBio's business model centers on offering its proprietary technologies as a service to clients, with a focus on developing and manufacturing biologics through plant-based systems. The company's technologies are applicable across multiple therapeutic areas, including fibrotic disease treatments, vaccine development, and enzyme replacement therapies. By providing these services, iBio supports clients in creating advanced biopharmaceutical products without the need for traditional manufacturing infrastructure. The company's revenue streams include the sale of its iBioLaunch and iBioModulator platforms, as well as product development and manufacturing services for biopharmaceutical clients. These services are tailored to meet the needs of partners seeking efficient, scalable production methods for biologics. iBio's focus on plant-based production differentiates it in the market, appealing to clients looking for innovative approaches to biologic manufacturing. iBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about iBio stock

Net Debt of iBio is -85.84 M USD in 2026.

Net Debt of iBio changed from -5.07 M USD to -85.84 M USD, representing a 1,591.78% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt iBio since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's iBio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — iBio

All Key Metrics — iBio